HIGHEST-EVER NET SALES FOR A SINGLE QUARTER

SECOND QUARTER OF 2014
•NET SALES amounted to MSEK 31.9 (26.5).
•OPERATING PROFIT totalled MSEK 5.3 (4.6).
•PROFIT AFTER TAX amounted to MSEK4.3 (3.8).
•PROFIT AFTER TAX PER SHARE was SEK 0.47 (0.42).
•CASH FLOW amounted to a negative MSEK 0.6 (neg: 2.6). Probi paid dividends of
MSEK 6.8 (6.8).

FIRST SIX MONTHS OF 2014
•NET SALES amounted to MSEK 58.3 (51.9).
•OPERATING PROFIT totalled MSEK 11.5 (10.6).
•PROFIT AFTER TAX amounted to MSEK 9.3 (8.7).
•PROFIT AFTER TAX PER SHARE was SEK 1.03 (0.96).
•CASH FLOW amounted to MSEK 3.0 (0.0). Probi paid dividends of MSEK 6.8 (6.8).

SIGNIFICANT EVENTS DURING THE SECOND QUARTER:
•Probi signed a distribution agreement with Sanofi Consumer Healthcare for the
launch of Probi Digestis® in South Korea.
•Probi signed a distribution agreement with Impexia for the launch of Probi
Digestis in Turkey.
•Study shows that Probi’s probiotics may reduce the risk of osteoporosis.
•Study shows that Probi’s probiotics increase iron absorption in women of child
-bearing age.
•Study shows that Probi’s probiotics are well tolerated by children treated with
antibiotics. A lower incidence of complaints such as headache and fever was also
reported for the active group, but no difference was observed for the frequency
of diarrhoea.
•Probi’s American partner NBTY/Solgar launched Probi’s digestive health capsules
in the UK market.

SIGNIFICANT EVENTS AFTER THE CLOSE OF THE PERIOD:
•Another study confirmed that Probi’s probiotics increase iron absorption in
women of child-bearing age.

CEO’S COMMENTS:
“Net sales of MSEK 31.9 in the second quarter are the company’s highest ever for
an individual quarter. The Consumer Healthcare business area continues to drive
growth, with net sales up 32% compared with the first six months of 2013. We see
a continued and highly positive trend in the North American market, where our
products are also being launched in the retail channel now. The launches in
South Korea have been successful and are making a significant contribution to
our strong growth. Good news was also announced in the research area during the
second quarter. Two studies showing that our probiotics may significantly
increase iron absorption in women of child-bearing age were concluded this year.
A product with bioavailable iron that is also gentle on the stomach is much
needed. In partnership with our distributors, we can now prepare for a product
launch in 2015,” says Peter Nählstedt, CEO of Probi.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Peter Nählstedt, CEO Probi, tel: +46 (0)46-286 89 23 or +46 (0)723-86 99 83, e
-mail: peter.nahlstedt@probi.se
Niklas Brandt, CFO Probi, tel: +46 (0)46-286 89 26 or +46 (0)706-62 98 83, e
-mail: niklas.brandt@probi.se

This information is such that Probi AB is required to disclose in accordance
with the Swedish Securities Market Act and/or the Financial Instruments Trading
Act. The information was submitted for publication on 19 August 2014 at 8.45
a.m.

This is a translation of the Swedish version of the interim report. When in
doubt, the Swedish wording prevails.

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company that develops
effective and well-documented probiotics. Through its world-leading research,
Probi has created a strong product portfolio in the gastrointestinal health and
immune system niches. Probi’s products are available to consumers in more than
30 countries worldwide. Probi’s customers are leading food, health-product and
pharmaceutical companies in the Functional Food and Consumer Healthcare
segments. In 2013, Probi had sales of MSEK 102. The Probi share is listed on
NASDAQ OMX Stockholm, Small Cap. Probi has about 3,500 shareholders. Read more
at www.probi.se.